Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series

Alejandro Llanos-Chea^{1

2}, Jason M Shapiro^{3

4}, Rachel W Winter^{5

6}, Logan Jerger^{1

2}, Timothy Menz^{3

4}, Meghan Gibson^{3

4}, Alison M Friedmann^{1

2}, Diana Treaba^{7

8}, Konstantinos Papamichael^{9

10}, Adam S Cheifetz^{9

10}, Sonia Friedman^{5

6}, Matthew J Hamilton^{5

6}, Harland S Winter^{11

12}

Affiliations

¹ Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital, CRPZ 5-560, 175 Cambridge Street, Boston, MA, 02114, USA.
² Harvard Medical School, CRPZ 5-560, 175 Cambridge Street, Boston, MA, 02114, USA.
³ Division of Pediatric Gastroenterology, Nutrition, and Liver Diseases, Hasbro Children's Hospital and Rhode Island Hospital, Hasbro Lower Level, 593 Eddy St., Providence, RI, 02903, USA.
⁴ Warren Alpert Medical School of Brown University, Hasbro Lower Level, 593 Eddy St., Providence, RI, 02903, USA.
⁵ Division of Gastroenterology, Brigham and Women's Hospital, Crohn's and Colitis Center, 75 Francis Street, Boston, MA, 02115, USA.
⁶ Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.
⁷ Department of Pathology, Rhode Island Hospital, The Miriam Hospital, Brown University, Box G-E5, Providence, RI, 02912, USA.
⁸ Warren Alpert Medical School of Brown University, Brown University, Box G-E5, Providence, RI, 02912, USA.
⁹ Division of Gastroenterology, Beth Israel Deaconess Medical Center, Beth Israel Deaconess Med Ctr., 330 Brookline Avenue, Rabb Rose 1, Boston, MA, 02215, USA.
¹⁰ Harvard Medical School, Beth Israel Deaconess Med Ctr., 330 Brookline Avenue, Rabb Rose 1, Boston, MA, 02215, USA.
¹¹ Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital, CRPZ 5-560, 175 Cambridge Street, Boston, MA, 02114, USA. hwinter@mgh.harvard.edu.
¹² Harvard Medical School, CRPZ 5-560, 175 Cambridge Street, Boston, MA, 02114, USA. hwinter@mgh.harvard.edu.

PMID: 33595782
DOI: 10.1007/s10620-021-06884-9

Case Reports

Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series

Alejandro Llanos-Chea et al. Dig Dis Sci. 2022 Jan.

. 2022 Jan;67(1):252-258.

doi: 10.1007/s10620-021-06884-9. Epub 2021 Feb 17.

Authors

Affiliations

¹ Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital, CRPZ 5-560, 175 Cambridge Street, Boston, MA, 02114, USA.
² Harvard Medical School, CRPZ 5-560, 175 Cambridge Street, Boston, MA, 02114, USA.
³ Division of Pediatric Gastroenterology, Nutrition, and Liver Diseases, Hasbro Children's Hospital and Rhode Island Hospital, Hasbro Lower Level, 593 Eddy St., Providence, RI, 02903, USA.
⁴ Warren Alpert Medical School of Brown University, Hasbro Lower Level, 593 Eddy St., Providence, RI, 02903, USA.
⁵ Division of Gastroenterology, Brigham and Women's Hospital, Crohn's and Colitis Center, 75 Francis Street, Boston, MA, 02115, USA.
⁶ Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.
⁷ Department of Pathology, Rhode Island Hospital, The Miriam Hospital, Brown University, Box G-E5, Providence, RI, 02912, USA.
⁸ Warren Alpert Medical School of Brown University, Brown University, Box G-E5, Providence, RI, 02912, USA.
⁹ Division of Gastroenterology, Beth Israel Deaconess Medical Center, Beth Israel Deaconess Med Ctr., 330 Brookline Avenue, Rabb Rose 1, Boston, MA, 02215, USA.
¹⁰ Harvard Medical School, Beth Israel Deaconess Med Ctr., 330 Brookline Avenue, Rabb Rose 1, Boston, MA, 02215, USA.
¹¹ Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital, CRPZ 5-560, 175 Cambridge Street, Boston, MA, 02114, USA. hwinter@mgh.harvard.edu.
¹² Harvard Medical School, CRPZ 5-560, 175 Cambridge Street, Boston, MA, 02114, USA. hwinter@mgh.harvard.edu.

PMID: 33595782
DOI: 10.1007/s10620-021-06884-9

Abstract

Background: Inflammatory bowel diseases (IBD) are often treated with anti-tumor necrosis factor alpha (anti-TNFα) medications. Concomitant treatment of IBD with anti-TNFα agents and immunomodulators appears to be associated with an increased risk for lymphoma.

Methods: Patients who developed lymphoma while on monotherapy with an anti-TNFα agent were identified at three centers. Institutional Review Board approval was obtained.

Results: Five adolescents and young adult patients with pediatric-onset IBD who were treated with infliximab (IFX) without exposure to thiopurines were subsequently diagnosed with lymphoma. Three of the five patients had bone involvement at presentation. Epstein-Barr virus was positive in 2 cases. Median time from diagnosis of IBD and exposure to IFX prior to diagnosis of lymphoma was 5 and 4.3 years, respectively.

Conclusions: This case series reports long-term follow-up for young patients with IBD who were treated with IFX monotherapy and developed lymphoma. Three of the five patients had bone involvement. In general, the risk of lymphoma following exposure to anti-TNFα medications alone remains low, but the incidence of primary bone lymphomas in IBD has not been reported. Studies examining longer exposure times may be needed to determine the true lymphoma risk in patients treated with IFX monotherapy.

Keywords: ANTI-TNFα; Adolescent; Inflammatory bowel diseases; Infliximab; Lymphoma; Young adult.

PubMed Disclaimer

Comment in

The Question That Doesn't Seem to Go Away: Cancer Risk of Anti-TNF Therapy.
Ledder O. Ledder O. Dig Dis Sci. 2022 Jan;67(1):6-7. doi: 10.1007/s10620-021-06883-w. Epub 2021 Feb 17. Dig Dis Sci. 2022. PMID: 33595781 No abstract available.

References

1. Dulai PS, Thompson KD, Blunt HB, Dubinsky MC, Siegel CA. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12:1443–51. https://doi.org/10.1016/j.cgh.2014.01.021 . - DOI - PubMed
1. Sokol H, Beaugerie L, Maynadie M, Laharie D, Dupas JL, Flourie B et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2063–2071. https://doi.org/10.1002/ibd.22889 . - DOI - PubMed
1. Messina C, Christie D, Zucca E, Gospodarowicz M, Ferreri AJ. Primary and secondary bone lymphomas. Cancer Treat Rev. 2015;41:235–246. https://doi.org/10.1016/j.ctrv.2015.02.001 . - DOI - PubMed
1. Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679–1686. https://doi.org/10.1001/jama.2017.16071 . - DOI - PubMed - PMC
1. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874–881. https://doi.org/10.1016/j.cgh.2009.01.004 . - DOI - PubMed - PMC

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Springer
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series

Affiliations

Lymphoma in Pediatric-Onset Inflammatory Bowel Disease Treated with Infliximab Monotherapy: A Case Series

Authors

Affiliations

Abstract

Comment in

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical